Analyst Price Targets — LENZ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 9:10 am | — | Piper Sandler | $12.00 | $9.99 | TheFly | Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler |
| October 27, 2025 10:52 am | Matthew Caufield | H.C. Wainwright | $56.00 | $30.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ) |
| October 10, 2025 10:47 am | — | Piper Sandler | $67.00 | $46.25 | TheFly | Lenz Therapeutics price target raised to $67 from $51 at Piper Sandler |
| April 14, 2025 10:36 am | Biren Amin | Piper Sandler | $51.00 | $23.24 | TheFly | Lenz Therapeutics assumed with an Overweight at Piper Sandler |
| August 15, 2024 8:44 am | Joseph Catanzaro | Piper Sandler | $36.00 | $22.25 | StreetInsider | Piper Sandler Reiterates Overweight Rating on LENZ Therapeutics Inc (LENZ) |
| August 15, 2024 4:58 am | Yigal Nochomovitz | Citigroup | $32.00 | $23.50 | StreetInsider | LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi |
Latest News for LENZ
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals
SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said.
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LENZ.
U.S. House Trading
No House trades found for LENZ.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.